Nonvitamin K antagonist oral anticoagulants (NOACs): the tide continues to come in

References

• ISTH Stpering Committee for World Thrombosis DayThrombosis: a major contributor to the global disease burdenJ Thromb Haemost2014121580159025302663
   PubMed Web of Science ®Google Scholar
• BlannADKhooCWThe prevention and treatment of venous thromboembolism with LMWHs and new anticoagulantsVasc Health Risk Manag2009569370419707288
   PubMedGoogle Scholar
• RivaNAgenoWPros and cons of vitamin K antagonists and non-vitamin K antagonist oral anticoagulantsSemin Thromb Hemost20154117818725703519
   PubMed Web of Science ®Google Scholar
• HustedSDe CaterinaRAndreottiFESC Working Group on Thrombosis Task Force on anticoagulants in heart disease. Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novelThromb Haemost201411178178224658395
   PubMed Web of Science ®Google Scholar
• StangierJRathgenKStahleHGansserDRothWThe pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjectsBr J Clin Pharmacol20076429230317506785
   PubMed Web of Science ®Google Scholar
• KubitzaDBeckaMVoithBZuehlsdorfMWensingGSafety, pharmacodynamics, and pharmacokinetics of single doses of BAY59-7939, an oral, direct factor Xa inhibitorClin Pharmacol Ther20057841242116198660
   PubMed Web of Science ®Google Scholar
• WongPCCrainEJXinBApixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studiesJ Thromb Haemost2008682082918315548
   PubMed Web of Science ®Google Scholar
• OgataKMendell-HararyJTachibanaMClinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteersJ Clin Pharmacol20105074375320081065
   PubMed Web of Science ®Google Scholar
• AhrensIPeterKLipGYBodeCDevelopment and clinical applications of novel oral anticoagulants. Part II. Drugs under clinical investigationDiscov Med20121344545022742650
   PubMed Web of Science ®Google Scholar
• CaldeiraDBarraMSantosATRisk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysisHeart201410055055624476812
   PubMed Web of Science ®Google Scholar
• PalladinoMMerliGThomsonLEvaluation of the oral direct factor Xa inhibitor – betrixabanExpert Opin Investig Drugs20132214651472
   PubMed Web of Science ®Google Scholar
• IwatsukiYSatoTMoritaniYBiochemical and pharmacological profile of darexaban, an oral direct factor Xa inhibitorEur J Pharmacol2011673495522040919
   PubMed Web of Science ®Google Scholar
• HashimotoTSuzukiKKiharaYAbsorption, metabolism and excretion of darexaban (YM150), a new direct factor Xa inhibitor in humansXenobiotica201343653454723167531
   PubMed Web of Science ®Google Scholar
• KakuSSuzukiMSaitohMDarexaban: anticoagulant effects in mice and human plasma in vitro, antithrombotic effects in thrombosis and bleeding models in mice and effects of anti-inhibitor coagulant complex and recombinant factor VIIaThromb Res201313145045623591155
   PubMed Web of Science ®Google Scholar
• KadokuraTGroenendaalDHeeringaMDarexaban (YM150), an oral direct factor Xa inhibitor, has no effect on the pharmacokinetics of digoxinEur J Drug Metab Pharmacokinet2014391923754514
   PubMed Web of Science ®Google Scholar
• GroenendaalDStrabachGGarcia-HernandezAThe pharmacokinetics of darexaban are not affected to a clinically relevant degree by rifampicin, a strong inducer of P-glycoprotein and CYP3A4Br J Clin Pharmacol201375244044922642721
   PubMed Web of Science ®Google Scholar
• SakonMNakamuraMDarexaban (YM150) prevents venous thromboembolism in Japanese patients undergoing major abdominal surgery: phase III randomized, mechanical prophylaxis-controlled, open-label studyThromb Res2012130e52e5922762942
   PubMed Web of Science ®Google Scholar
• FujiTNakamuraMTakeuchiMDarexaban for the prevention of venous thromboembolism in Asian patients undergoing orthopedic surgery: results from 2 randomized, placebo-controlled, double-blind studiesClin Appl Thromb Hemost20142019921122952213
   PubMed Web of Science ®Google Scholar
• ErikssonBIAgnelliGGallusASDarexaban (YM150) versus enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a randomised phase IIb dose confirmation study (ONYX-3)Thromb Haemost201411121322524136153
   PubMed Web of Science ®Google Scholar
• StegPGMehtaSRJukemaJWRUBY-1 investigators. RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndromeEur Heart J2011322541255421878434
   PubMed Web of Science ®Google Scholar
• MegaJLBraunwaldEWiviottSDATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndromeN Engl J Med201236691922077192
   PubMed Web of Science ®Google Scholar
• GanetskyVSHadleyDEThomasTFRole of novel and emerging oral anticoagulants for secondary prevention of acute coronary syndromesPharmacotherapy20143459060424338703
   PubMed Web of Science ®Google Scholar
• ChanNCBhagirathVEikelboomJWProfile of betrixaban and its potential in the prevention and treatment of venous thromboembolismVasc Health Risk Manag20151134335126170684
   PubMed Web of Science ®Google Scholar
• GreinacherAThieleTSellengKReversal of anticoagulants: an overview of current developmentsThromb Haemost201511393194225832311
   PubMed Web of Science ®Google Scholar
• GlundSMoschettiVNorrisSA randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatranThromb Haemost201511394395125789661
   PubMed Web of Science ®Google Scholar
• PollackCVJrReillyPABernsteinRDesign and rationale for RE-VERSE AD: a phase 3 study of idarucizumab, a specific reversal agent for dabigatranThromb Haemost2015114119820526020620
   PubMed Web of Science ®Google Scholar
• LuGDeGuzmanFRHollenbachSJA specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor XaNat Med20131944645123455714
   PubMed Web of Science ®Google Scholar
• FawoleADawHACrowtherMAPractical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixabanCleve Clin J Med20138044345123821689
   PubMed Web of Science ®Google Scholar
• HolsterILHunfieldNGMKuipersEJKruipMJHATjwaETTLOn the treatment of new oral anticoagulant-associated gastrointestinal haemorrhageJ Gastrointestin Liver Dis20132222923123799225
   PubMed Web of Science ®Google Scholar
• MajeedASchulmanSBleeding and antidotes in new oral anticoagulantsBest Pract Res Clin Haematol20132619120223953907
   PubMed Web of Science ®Google Scholar
• SteinerTBohmMDichgansMRecommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs) apixaban, dabigatran and rivaroxabanClin Res Cardiol201310239941223669868
   PubMed Web of Science ®Google Scholar
• CushmanMLimWZakaiNAClinical Practice Guide on Antithrombotic Drug Dosing and Management of Anti-Thrombotic Drug- Associated Bleeding Complications in Adults2014 Available from: http://www.hematology.org/Clinicians/Guidelines-Quality/Quick-Ref/2869.aspx. February 2014 EditionAccessed August 3, 2015
   Google Scholar
• DinkelaarJPatiwaelSHarenbergJLeyteABrinkmanHJGlobal coagulation tests: their applicability for measuring direct factor Xa- and thrombin inhibition and reversal of anticoagulation by prothrombin complex concentrateClin Chem Lab Med2014521615162324902009
   PubMed Web of Science ®Google Scholar
• BlannADNon-vitamin K antagonist oral anticoagulants (NOACs): a view from the laboratoryBr J Biomed Sci20147115816725562993
   PubMed Web of Science ®Google Scholar
• BaglinTHillarpATripodiAElalamyIBullerHAgenoWMeasuring oral direct inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the ISTHJ Thromb Haemost201311756760
   Google Scholar
• KitchenSGrayEMackieIBaglinTMakrisMMeasurement of non-coumarin anticoagulants and their effects on tests of haemostasis: guidance from the British Committee for standards in haematologyBr J Haematol210416683084124930477
   PubMedGoogle Scholar